Vericel (VCEL) Research & Development (2010 - 2026)
Vericel's (VCEL) quarterly Research & Development came in at $8.1 million in Q1 2026, up 11.61% year-on-year from $7.3 million in Q1 2025, and up 11.73% quarter-over-quarter from $7.3 million in Q4 2025.
Vericel (VCEL) Research & Development (2010 - 2026) Analysis & Trends
Vericel has disclosed Research & Development across 17 years of filings, most recently posting $8.1 million for Q1 2026.
- Research & Development for Q1 2026 came in at $8.1 million, up 11.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $28.4 million (up 10.79% YoY), and the FY2025 annual result was $27.6 million, up 11.15% from the prior year.
- Research & Development came in at $8.1 million for Q1 2026 at Vericel, up from $7.3 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $8.1 million in Q1 2026 to a low of $4.8 million in Q2 2022.
- The 5-year median for Research & Development is $5.7 million (2023), against an average of $6.0 million.
- Peak annual rise in Research & Development reached 47.33% in 2025, while the deepest fall reached 8.58% in 2025.
- Vericel's Research & Development stood at $5.2 million in 2022, then declined by 6.56% to $4.9 million in 2023, then rose by 0.45% to $4.9 million in 2024, then jumped by 47.33% to $7.3 million in 2025, then advanced by 11.73% to $8.1 million in 2026.
- The last three Research & Development figures came in at $8.1 million (Q1 2026), $7.3 million (Q4 2025), and $6.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -2.30 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 1.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -58.00 Mn |
| 10 | Vericel | 2.04 Bn | 1.90 Bn | 49.27 Mn | 8.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.10 Mn |
| Dec 31, 2025 | 7.25 Mn |
| Sep 30, 2025 | 6.32 Mn |
| Jun 30, 2025 | 6.73 Mn |
| Mar 31, 2025 | 7.26 Mn |
| Dec 31, 2024 | 4.92 Mn |
| Sep 30, 2024 | 6.09 Mn |
| Jun 30, 2024 | 7.36 Mn |
| Mar 31, 2024 | 6.42 Mn |
| Dec 31, 2023 | 4.90 Mn |
| Sep 30, 2023 | 5.68 Mn |
| Jun 30, 2023 | 5.25 Mn |
| Mar 31, 2023 | 5.21 Mn |
| Dec 31, 2022 | 5.25 Mn |
| Sep 30, 2022 | 5.05 Mn |
| Jun 30, 2022 | 4.79 Mn |
| Mar 31, 2022 | 4.86 Mn |
| Dec 31, 2021 | 3.92 Mn |
| Sep 30, 2021 | 4.28 Mn |
| Jun 30, 2021 | 4.45 Mn |